Overview

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).

Phase:

PHASE2

Details

Lead Sponsor:

AstraZeneca

Treatments:

osimertinib